Details
| Stereochemistry | RACEMIC |
| Molecular Formula | C6H12O21P6 |
| Molecular Weight | 605.9895 |
| Optical Activity | ( + / - ) |
| Defined Stereocenters | 6 / 6 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
OP1(=O)O[C@@H]2[C@H](OP(O)(=O)O1)[C@@H]3OP(O)(=O)OP(O)(=O)O[C@H]3[C@@H]4OP(O)(=O)OP(O)(=O)O[C@@H]24
InChI
InChIKey=HEDKSUBRULAYNO-XCMZKKERSA-N
InChI=1S/C6H12O21P6/c7-28(8)19-1-2(20-29(9,10)25-28)4-6(24-33(17,18)27-32(15,16)23-4)5-3(1)21-30(11,12)26-31(13,14)22-5/h1-6H,(H,7,8)(H,9,10)(H,11,12)(H,13,14)(H,15,16)(H,17,18)/t1-,2-,3-,4+,5-,6-/m1/s1
Myo-inositol trispyrophosphate (also known as OXY111A) is a synthetic allosteric effector of hemoglobin which increases the regulated oxygen releasing capacity of red blood cells. Myo-inositol trispyrophosphate is taken up by red blood cells via the band 3.1 transporter and promotes the dissociation of oxygen from hemoglobin specifically under hypoxic conditions and has the potential to prevent hypoxia without affecting the oxygen levels in the surrounding normoxic cells. In phase I/II clinical trial Myo-inositol trispyrophosphate shows encouraging results in patients with primary and secondary hepatopancreatobiliary tumors.
Approval Year
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
1791813
Created by
admin on Mon Mar 31 22:35:38 GMT 2025 , Edited by admin on Mon Mar 31 22:35:38 GMT 2025
|
PRIMARY | |||
|
DTXSID301029636
Created by
admin on Mon Mar 31 22:35:38 GMT 2025 , Edited by admin on Mon Mar 31 22:35:38 GMT 2025
|
PRIMARY | |||
|
802590-64-3
Created by
admin on Mon Mar 31 22:35:38 GMT 2025 , Edited by admin on Mon Mar 31 22:35:38 GMT 2025
|
PRIMARY | |||
|
116EYZ0PPX
Created by
admin on Mon Mar 31 22:35:38 GMT 2025 , Edited by admin on Mon Mar 31 22:35:38 GMT 2025
|
PRIMARY |
SUBSTANCE RECORD
